Drugs / PEGDINETANIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01146171 | Nov 2013 → Jan 2015 | neoplasm | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT00768911 | Oct 2008 → Oct 2010 | glioblastoma | Adnexus, A Bristol-Myers Squibb R&D Company | Unknown | No outcome recorded |
| Phase 1 | NCT00374179 | Aug 2006 → Nov 2008 | cancer | Adnexus, A Bristol-Myers Squibb R&D Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00562419 | Oct 2007 → Jun 2011 | glioblastoma | Adnexus, A Bristol-Myers Squibb R&D Company | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00851045 Comparator | Oct 2009 → Sep 2011 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00850577 Comparator | Jun 2009 → Aug 2013 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGDINETANIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108356 ↗ |
| Known as | Angiocept | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108356 ↗ |
| Known as | BMS-844203 | “Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.” PMID 21224368 ↗ Jan 2011 |
| Known as | CT-322 | “BMS-844203 (CT-322)” NCT01146171 ↗ |
| Known as | VEGFR-2 INHIBITOR PEPTIDE CT-322 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108356 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL2108356 ↗1“a VEGFR-2 inhibitor” PMID 21224368 ↗ Jan 2011 |
| Modality | Protein / enzyme biologic | “the first human fibronectin domain-based targeted biologic (Adnectin) to enter clinical studies” PMID 21224368 ↗ Jan 2011 |
| Route | Intravenous | “Patients with advanced solid malignancies were treated with escalating doses of CT-322 intravenously (i.v.) weekly (qw), or biweekly (q2w).” PMID 21224368 ↗ Jan 2011 |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL2108356 ↗ |